Ipsen Relocating to Cambridge
After selling its hemophilia drug program to an Illinois company earlier this year, French pharmaceutical company Ipsen has announced it will relocate its U.S. research and development activities to Cambridge in 2014.
The Massachusetts Life Sciences Center, which previously administered a research matching grant to Ipsen, announced the move. According to the center, Ipsen signed an 11-year lease on a 62,600-square-foot laboratory and office space at 650 East Kendall St. in Cambridge. The site will be key for the development of targeted therapies across Ipsen's drug specialties and peptides the Life Sciences Center said.
Ipsen announced in March it was selling its hemophilia drug program with its partner, Inspiration Biopharmaceuticals, after Inspiration filed for Chapter 11 bankruptcy protection. It operated out of a facility on Maple Street in Milford, and the buyer, Baxter International Inc., said it was offering employment to Ipsen's employees and would continue operations in Milford for the foreseeable future.
Cynthia Sylvestre, Ipsen's Milford site head, confirmed that Baxter will continue operations in Milford. She said Ipsen transitioned about 75 employees to Baxter following the sale of its hemophilia program, and that program is continuing.
Ipsen operated its Milford facility for roughly 30 years before selling the hemophilia program to Baxter. Sylvestre said the company has been leasing space from Baxter in Milford following the sale, and hopes to be moved into its new Cambridge facility by the summer of next year.
WBJ Web Partners
Most Recent
Most Recent
0 Comments